脂肪组织中的热生成:上腺和非上腺途径
Md Arafat Hossain1, Ankita Poojari1, Atefeh Rabiee1
1Department of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA 95211, USA.
Cells
|January 28, 2026
概括
肥胖管理需要超越传统途径的新策略. 本综述探讨了安全和有效的能源支出的非上腺素目标和干预措施,为可持续的体重控制提供了希望.
科学领域:
- 代谢研究的研究.
- 脂肪组织生物学 脂肪组织生物学
- 肥胖治疗方法 肥胖治疗方法
背景情况:
- 肥胖是一种由能量失衡驱动的全球流行病.
- 棕色 (BAT) 和色脂肪组织通过非热生成 (NST) 促进能量消耗 (EE).
- 规范性上腺素通路在人类肥胖治疗中表现出有限的翻译成功.
研究的目的:
- 审查激活热生成的替代性,非上腺素途径.
- 评估针对这些途径的药理和非药理干预措施.
- 弥合动物和人类肥胖研究之间的翻译差距.
主要方法:
- 关于替代热生成机制的综合文献综述.
- 对G蛋白结合受体 (GPCR),离子通道和激素信号的分析.
- 评估干预措施,包括暴露于寒冷,运动,饮食和新药药物.
主要成果:
- 非上腺素路径 (例如,TGR5,GLP-1R,SERCA调节器) 提供了有前途的替代品.
- 独立于UCP1的机制和徒劳的基质循环有助于热生成.
- 结合上腺和非上腺疗法的多式疗法显示出潜力.
结论:
- 非上腺和UCP1独立的机制对于人类的发热至关重要.
- 整合不同的治疗策略是有效的肥胖管理的关键.
- 未来的研究应该专注于可持续的EE的多式联络和组织特异性方法.
相关概念视频
Adrenergic Agonists: Therapeutic Uses
1.9K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.9K
Adrenergic Neurons: Neurotransmission
5.3K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
5.3K
Adrenergic Agonists: Therapeutic Classification
1.6K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.6K
Adrenergic Receptors (Adrenoceptors): Classification
4.9K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
4.9K
Adrenergic Receptors: ɑ Subtype
2.9K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.9K
Adrenergic Receptors: β Subtype
3.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.7K


